Home / Deep Research / Bilateral Striopallidodentate Calcinosis

Bilateral Striopallidodentate Calcinosis

Question

2026-04-14
Cyberian Codex MONDO:0008947 Model: codex-local-synthesis 13 citations

Question

Codex secondary synthesis for disorder curation.

Curation Summary

  • Disease anchor: MONDO:0008947 (bilateral striopallidodentate calcinosis), with exact MONDO synonyms including PFBC, Primary Familial Brain Calcification, and narrow synonym Fahr disease.
  • Curation strategy: keep one disease/root page and document heterogeneity inside it. Do not split into multiple premature gene pages.
  • YAML evidence policy: only PMID-backed abstract quotes that can survive validate-references.

Disease Framing

  • BSPDC/PFBC is the same broad disease spectrum for this curation purpose.
  • The 2025 Brain review (PMID:40344186) states: To date, seven genes have been linked to PFBC.
  • Recent literature supports two high-level subtype buckets for the parent page:
  • Autosomal dominant PFBC: SLC20A2, XPR1, PDGFRB, PDGFB
  • Autosomal recessive PFBC: MYORG, JAM2, NAA60
  • I did not promote older, less stable candidate-gene mentions into the YAML unless I had direct and current PMID-backed support consistent with the current core-gene set.

Mechanistic Synthesis

  • Shared mechanism 1: phosphate transport dysregulation.
  • SLC20A2 is the major dominant phosphate-import gene (PMID:32506582).
  • XPR1 adds the complementary phosphate-export defect (PMID:25938945).
  • NAA60 converges on the same axis by lowering cell-surface SLC20A2 and extracellular phosphate uptake (PMID:38480682).
  • Shared mechanism 2: neurovascular-unit dysfunction.
  • PDGFB / PDGFRB connect PFBC to endothelial-pericyte biology and blood-brain barrier maintenance (PMID:23913003, PMID:23255827).
  • JAM2 makes the neurovascular-unit hypothesis explicit through impaired cell-cell adhesion (PMID:31851307).
  • MYORG is likely in the same broader pathway family, but the most validator-safe abstract wording is still more cautious (PMID:30656188).
  • Emerging mechanistic theme not over-modeled in YAML:
  • PMID:40344186 links NAA60 and SLC20A2 to Golgi integrity and highlights Golgi fragmentation as an emerging PFBC topic.

Phenotype Synthesis

  • Core parent-page phenotypes best supported by abstract-level quotes:
  • intracranial calcification / bilateral basal ganglia and extra-basal calcification
  • parkinsonism
  • cognitive impairment
  • psychosis / psychiatric presentation
  • Heterogeneity point worth preserving:
  • recessive disease is generally more severe and can include seizures and heavier cortical involvement (PMID:31851307).
  • I avoided overcommitting to additional phenotypes unless I had a clean HPO mapping plus an exact abstract sentence.

Treatment Synthesis

  • Current clinically supported treatment remains symptomatic rather than disease-modifying.
  • PMID:39036637 supports dopaminergic replacement therapy for PFBC-associated parkinsonism.
  • The strongest emerging precision-treatment paper is subtype-specific and preclinical.
  • PMID:39121859 shows ASO-mediated splice correction as a potential therapy for SLC20A2 haploinsufficiency.
  • I kept treatment modeling conservative:
  • one symptomatic pharmacotherapy entry
  • one experimental ASO entry

YAML Decisions

  • Included:
  • one spectrum/root disorder page
  • two inheritance-level subtypes
  • seven causative genes with direct support
  • two shared mechanism nodes
  • four core phenotypes plus one recessive-severity phenotype
  • one symptomatic and one experimental treatment
  • Deliberately not included:
  • separate gene-specific disorder pages
  • secondary/idiopathic basal ganglia calcification syndromes outside MONDO:0008947
  • weaker or unstable gene claims not anchored by current direct PMID evidence

PMID Set Used For YAML